Purchase this article with an account.
Domenico Lepore, Lorenzo Orazi, Marco H. Ji, Giulia Maria Amorelli, Fernando Molle, Graham E Quinn; Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: FA vs OCT-A at 4 years of age. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3755. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study long term FA and OCT-A findings in a single center randomized study aimed to compared traditional laser treatment for Type 1 retinopathy of prematurity (ROP) with intravitreal injection of bevacizumab in the fellow eye.
Twenty-one inborn babies with type 1 zone 1 ROP were included in the study. One eye was randomized to receive an intravitreal injection of 0.5mg bevacizumab; the fellow eye received conventional laser photoablation. Fluorescein angiography, OCT and OCT-A images from 6 subjects (12 eyes) were obtained 4 years after treatment.Fluorescein angiographic findings were classified as previously described. OCT and OCT-A foveal structure was analysed and differences calculated in pixels with ImageJ software.
FA demonstrated a well-defined foveal avascular zone in all 12 eyes. All bevacizumab-treated eyes showed avascular peripheral retina with vascular abnormalities. On OCT in all subjects, bevacizumab-treated eyes tended to have thinner fovea than laser-treated eyes; OCT-A showed in all eyes a persistent superficial capillary network in the foveal region.
different imaging techniques are complementary in this study. Further studies are need to understand different aspects of the developing foveal structure.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only